key: cord-0828375-18j1iw9r
authors: Zeng, Yudan; Lin, Dongtao; Gao, Mengqian; Du, Guoxia; Cai, Yongming
title: Systematic evaluation of the prognostic and immunological role of PDLIM2 across 33 cancer types
date: 2022-02-04
journal: Sci Rep
DOI: 10.1038/s41598-022-05987-1
sha: 092f1209feae75107663c107f7f23055b3e94d42
doc_id: 828375
cord_uid: 18j1iw9r

The protein PDLIM2 regulates the stability of various transcription factors and is required for polarized cell migration. However, the clinical relevance and immune infiltration of PDLIM2 in cancer are not well-understood. We utilized The Cancer Genome Atlas and Genotype-Tissue Expression database to characterize alterations in PDLIM2 in pan-cancer. TIMER was used to explore PDLIM2 expression and immune infiltration levels. We assessed the correlation between PDLIM2 expression and immune-associated gene expression, immune score, tumor mutation burden, and DNA microsatellite instability. PDLIM2 significantly affected the prognosis of various cancers. Increased expression of PDLIM2 was significantly correlated with the tumor grade in seven types of tumors. The expression level of PDLIM2 was positively correlated with immune infiltrates, including B cells, CD8+ T cells, CD4+ T cells, neutrophils, macrophages, and dendritic cells in bladder urothelial, kidney renal papillary cell, and colon adenocarcinoma. High expression levels of PDLIM2 tended to be associated with higher immune and stromal scores. PDLIM2 expression was associated with the tumor mutation burden in 12 cancer types and microsatellite instability in 5 cancer types. PDLIM2 levels were strongly correlated with diverse immune-related genes. PDLIM2 can act as a prognostic-related therapeutic target and is correlated with immune infiltrates in pan-cancer.

Prognostic potential of PDLIM2 in cancers. We investigated whether PDLIM2 expression was correlated with prognosis in patients with cancer. First, the impact of PDLIM2 expression on overall survival was analyzed using univariate survival analysis. As shown in Fig. 2a , multiple cancer types exhibited a significant association between patient prognosis and PDLIM2 expression, including breast, kidney, blood, brain, and esophageal cancer. We additionally employed the Kaplan-Meier method to assess how PDLIM2 expression is related to prognosis in various cancer types, revealing its elevation to be significantly linked with adenoid cystic carcinoma (ACC; P = 0.008), BLCA (P = 0.038), acute myeloid leukemia (P < 0.001), and LUSC (P = 0.037) (Fig. 2b-e) . In contrast, reduced PDLIM2 expression was correlated with poor prognosis in thymoma (P = 0.04) (Fig. 2f) .

To eliminate the influence of non-tumor-related death factors, we analyzed the relationship between gene expression and disease-specific survival. Notably, PDLIM2 expression significantly affected the prognosis of four types of cancers ( Fig. 3a-d) , including ACC (P = 0.004), BLCA (P = 0.01), COAD (P = 0.008), and KIRP (P = 0.006). Therefore, high PDLIM2 expression may be an independent risk factor for poor prognosis in these four types of cancers. Correlation between PDLIM2 expression and immune cell infiltration. Immune cell infiltration affects survival and tumor metastasis in patients. In the previous analysis, PDLIM2 expression levels were found to be associated with prognosis and metastasis in BLCA, KIRP, and COAD. The correlation between the expression level of PDLIM2 and the six types of infiltrating immune cells in these three tumor types is shown in Fig. 5 . PDLIM2 expression was negatively correlated with tumor purity. Tumor purity refers to the proportion of cancer cells in tumor samples. Tumors with low tumor purity tend to have a higher mutational load and stronger immune phenotypes 21, 22 . The expression level of PDLIM2 was positively correlated with macrophages (R = 0.415, P = 1.17e−16) and dendritic cells (R = 0.301, P = 4.56e−09) in BLCA; CD4+ T cells (R = 0.338, P = 3.49e−12), macrophages (R = 0.329,P = 1.16e−11), neutrophils (R = 0.321, P = 4.62e−11), and dendritic cells (R = 0.348, P = 7.42e−13) in COAD; and B cells (R = 0.406, P = 1.45e−11), CD8+ T cells (R = 0.389, P = 9.44e−11), and dendritic cells (R = 0.355, P = 5.29e−09) in KIRP.

Correlation between PDLIM2 expression level and immune cell markers. High PDLIM2 expression was positively correlated with immune cell infiltration. We further investigated the correlation between PDLIM2 expression levels and immunological marker sets in BLCA, COAD, and KIRP ( Table 1 ). The results revealed that the PDLIM2 expression level was positively correlated with the expression of most immune cell Correlation between PDLIM2 expression level and tumor microenvironment. The expression of PDLIM2 may be closely related to immune escape in BLCA and KIRP. The immune score predicts the response to tumor immunotherapy. Analysis of the relationship between PDLIM2 expression and immune scores revealed that higher PDLIM2 expression levels were associated with higher immune scores and stromal scores (Fig. 6) . www.nature.com/scientificreports/ We next examined the relationship between the expression of immune checkpoint genes (including 11 immunostimulators and 7 immunoinhibitors) and PDLIM2. The expression of PDLIM2 was significantly associated with that of immune checkpoint genes ( Table 2 ).

Previous studies focused on the prognostic role of tumor mutational burden (TMB) in immunotherapy in many cancer types; here, we counted the TMB of each tumor sample and analyzed the relationship between PDLIM2 expression and TMB in 12 different cancer types. PDLIM2 was negatively correlated with the TMB in BLCA, cholangiocarcinoma, COAD, LIHC, LUAD, LUSC, paraganglioma, prostate adenocarcinoma, pulmonary enteric adenocarcinoma, stomach adenocarcinoma, and thymoma and positively correlated with ACC (Fig. 7a) .

The microsatellite instability (MSI) status of different solid tumors was significantly different from that of checkpoint inhibitor drugs for the immune response rates. Several studies have shown that MSI is closely related to tumor occurrence. Analysis of the correlation between PDLIM2 expression and MSI revealed a correlation mainly in adenocarcinoma (Fig. 7b ). PDLIM2 expression was positively correlated with MSI in breast invasive Correlation between PDLIM2 expression level and immune checkpoint genes. Immune checkpoints are signaling pathways responsible for downregulating the immune response to avoid destruction of endogenous targets and temper the peripheral immune response. We analyzed the relationship between the expression of common immune checkpoint genes and PDLIM2 in 33 cancer types. The results showed that PDLIM2 expression was significantly associated with immune checkpoint expression in most tumor types, although there was no significant relationship in ACC, esophageal carcinoma, LIHC, uterine carcinosarcoma, and uveal melanoma (Fig. 8) . Notably, PDLIM2 was related not only to the common targets of checkpoint inhibitors (PDCD1, CTLA4, etc.), but also to targets of stimulatory checkpoint molecules (CD27, ICOS, etc.).

PDLIM2 is a member of the PDZ-LIM family, whose PDZ structural domain is a functional module for protein-protein inter-recognition and the LIM structural domain is a structural domain for protein-protein interactions. These structures play important roles in cell differentiation and signal transduction 23 . PDLIM2 is crucial for tumorigenesis and progression and is closely related to the immune system. We comprehensively characterized PDLIM2 across 33 cancer types and highlight the potential clinical utility of immunity therapy for PDLIM2 expression.

The expression of PDLIM2 is related to both tumor inhibition and tumorigenesis 11 . Our results support the dual role of PDLIM2 in cancer. PDLIM2 is a putative tumor-suppressor protein that is inhibited by epigenetics in different cancers and is highly expressed in most adjacent noncancerous tissues. PDLIM2, as a cytoskeleton component, can reverse the growth of cancer cells by regulating promoter methylation. Repression of PDLIM2 has been shown to continuously activate nuclear factor-κB and STAT3, eventually leading to tumorigenesis and tumor maintenance 24 . Sun et al. found that PDLIM2 is inhibited in lung cancer, which is associated with a poor prognosis 14 . However, in our study, PDLIM2 led to different prognoses in different types of lung cancer. As seen by clinical correlation analysis, the reason for this discrepancy may be that high PDLIM2 expression contributes to the poor prognosis of LUSC patients by affecting lymph node metastasis. In addition, PDLIM2 was also highly expressed in invasive cancer cells. Zhao et al. reported that PDLIM2 promotes ovarian cancer growth in vivo and in vitro through NOS2-derived nitric oxide signaling 25 . Another study showed that PDLIM2 inhibition effectively reduced the tumor growth and invasiveness of human castration-resistant prostate cancer cells 26 . A recent study revealed that PDLIM2 was highly correlated with tumor growth and metastasis in renal cell carcinoma in a mouse knockout model 27 . We also observed significant correlations between PDLIM2 expression and patient survival in thymic carcinomas, which has not been widely reported in previous studies. Additionally, gene expression was related to clinical stage in seven tumors, suggesting that PDLIM2 is involved in promoting cancer progression or metastasis. 1,25 (OH) 2D3-induced adhesion of cancer cells to the extracellular matrix is mediated by PDLIM2 28 . PDLIM2 promotes tumor angiogenesis by activating the MAPK/ERK pathway 26 depending on the tumor microenvironment 29 . These results confirm the prognostic value of PDLIM2 in some specific types of cancers and that increased and decreased PDLIM2 expression have different prognostic values depending on the cancer type. www.nature.com/scientificreports/ Importantly, we found that PDLIM2 functions in the recruitment and activation of immune infiltrating cells. PDLIM2 participates in the differentiation of TAMs into M2 macrophages; TIMER database results showed positively correlated with the infiltration of B cells and macrophages in BLCA and KIRP. We showed that PDLIM2 expression was not related to M1 macrophages but was positively correlated with most M2 macrophage markers. A previous study revealed that PDLIM2 leads to the recruitment of M2 macrophages in ovarian cancer 25 . TAMs lead to poor prognosis of tumors by inhibiting the immune and secreting various factors that promote tumor growth 30 . M2 macrophages can promote tumors growth and secrete IL-10, transforming growth factor β, and other mediators that contribute to establishing a tumor-tolerant microenvironment and angiogenic factors 31 . IL-10 (a TAM marker) is often associated with decreased T-cell activation 32 . In addition, PDLIM2 may inhibit T cell-mediated immunity and is involved in the immune escape of tumors. The correlation between PDLIM2 expression and immune cell marker genes suggests that PDLIM2 can control the infiltration and interaction of immune cells in the tumor microenvironment, and Treg-like immunosuppression can be induced by inducing Foxp3 expression in naïve T cells 33 . Dendritic cells can lead to tumor metastasis by enhancing the Treg response and suppressing the cytotoxicity of CD8+ T cells 34 . Notably, PDLIM2 expression was strongly correlated with TIM-3 in bladder cancer and with PDCD1, CTLA4, GZMB, and LAG3 in KIRP. These genes are common markers for T cell exhaustion, which is one of the main factors of immune dysfunction in patients with cancer. PD-1-or CTL-4-mediated pathways suppress T cell function 35 . LAG3 can inhibit T cells without relying on CD4 36 . T cell exhaustion can be partially reversed clinically using immune checkpoint inhibitors 37 . Patients with high PDLIM2 expression showed higher T cell infiltration; thus, these patients are more likely to benefit from immune checkpoint blockade against PD-1 and CTLA-4. Generally, PDLIM2 can mediate the differentiation of M2 macrophages and T cell exhaustion, thus avoiding immune detection.

Another key finding of this study is that PDLIM2 can be used as a therapeutic target for epigenetic drugs combined with immune checkpoint inhibitors. Patients with high expression benefit more from immunotherapy. PDLIM2 expression was associated with the TMB in 12 cancer types and MSI in five cancer types. TMB [38] [39] [40] and MSI are important in the immunotherapy response. The TMB is a pan-cancer genomic biomarker related to the efficacy of checkpoint inhibitors. A higher TMB is an easier target for tumor immunotherapy. MSI 41 is also an indicator of the efficacy of immunotherapy and was first used in colon cancer. Interestingly, although MSI indicators are more suitable for digestive system tumors, there is no correlation between PDLIM2 and MSI. PDLIM2 is a potential target for combination therapy for cancer. Notably, the expression of PDLIM2 was significantly associated with immune checkpoint expression in most tumor types. Guo and Qu suggested that PDLIM2 can www.nature.com/scientificreports/ be used as an epigenetic drug with immunomodulatory potential in combined immunotherapy for cancer 42 . Administration of epigenetic drugs can also enhance the efficacy of immunological checkpoint treatments 43 . There were some limitations to this study. First, all analyses were performed using public datasets. Our findings should be verified in animal experiments and hospitalized patients. Second, although we found that the expression of PDLIM2 is associated with tumor immune cell infiltration and survival, we did not confirm that PDLIM2 affects the survival of patients through immune infiltration, and the prognostic value of this protein in tumor immune mechanisms and immune signals should be further explored. Finally, we only included total PDLIM2 RNA levels in this study, without considering RNA variants and protein modifications.

In summary, PDLIM2 can affect pan-cancer prognosis and participate in immune regulation. Particularly, in BLCA and KIRP, PDLIM2 is mainly associated with immunosuppression in tumor tissues. Therefore, PDLIM2 is useful as a prognostic-related biomarker and is correlated with immune infiltrates in the BLCA and KIRP. Moreover, PDLIM2 may be a valuable therapeutic target for tumor immunotherapy in 33 cancer types. www.nature.com/scientificreports/ information from TCGA Pan-CANCER (pan can) including 41 datasets and 12,591 samples to obtain data on disease-specific survival and DFI. After eliminating cases with insufficient or missing data for age and the overall survival time, 11,057 samples were included in the study (Supplementary Table S2 ).

Gene expression analysis. We used "wilcox.test" to analyze the differential expression of total PDLIM2 RNA in normal and tumor tissue samples from 33 cancer types in TCGA database and drew a box plot using "ggpubr. " To compensate for the lack of normal organization in TCGA database, we added the GTEx(Genotype-Tissue Expression) database 46 for analysis; this part of the analysis was mainly performed in the Gene Expression Profile of the GEPIA2 database 47 (Gene Expression Profiling Interactive Analysis, http:// gepia2. cancer-pku. cn/# analy sis). The main parameters were as follows: gene, PDLIM2; differential methods, analysis of variance; q-value cutoff, 0.05; matched normal data: match TCGA normal and GTEx data.

Survival clinical analysis. Univariate survival analysis was performed using the Kaplan-Meier survival" package 48 . According to the median PDLIM2 expression level, patients with cancer were divided into low-and high-expression groups. Cox regression analysis was performed only for overall survival (OS). Kaplan-Meier analysis was conducted to compare the survival (OS, DDS, and DFI) differences between the low-and highexpression groups. A P value less than 0.05 was considered as the threshold in the Kaplan-Meier analysis results. The "survival" package was used for survival analysis. We used the R package "forestplot" to draw the forest map in Cox survival analysis and R package "survivminer" to draw the Kaplan-Meier survival curve.

A stage plot using the tumor stage as a variable was plotted to analyze the relationship between the expression level of PDLIM2 and tumor metastasis in different cancers. R package "limma" 49 was used to analyze the differential expression of PDLIM2 in different clinical stages, and the box diagram was drawn using "ggpubr. " TIMER database analysis. TIMER 50 (Tumor Immune Estimation Resource, https:// cistr ome. shiny apps.

io/ timer/) can use RNA-sequencing expression profile data to detect the infiltration of immune cells in tumor tissue. We applied the Gene of Immune Association module to explore the correlation between PDLIM2 expression and the abundance of immune infiltrates in BLCA, KIRP, and COAD. We imported "PDLIM2" in gene symbol; selected BLCA, KIRP, and COAD for cancer types; and chose B cells, CD4+ T cells, neutrophils, CD8+ T cells, macrophages, and dendritic cells for immune infiltrates.

Mutation analysis. TMB is a useful biomarker for predicting the prognosis and efficacy of immunotherapy.

We calculated the TMB of the 33 tumor types using mutation data. Perl scripts were written to extract genomic alterations, and calculate the TMB of the patients.TMB refers to the number of somatic mutations per million bases in tumor tissue 51 . MSI values were derived from TCGA database. We then analyzed the correlation between PDLIM2, TMB, and MSI and designed a radar map using the R-package "fmsb. " Correlation analysis was performed using Spearman's correlation.

Immunological correlation analysis. In the tumor microenvironment, immune cells and stromal cells are two main types of non-tumor components and were suggested to be valuable in the diagnosis and prognosis of tumors. We used R package "estimate" 52 to calculate the immune score and stromal score for BLCA and KIRP. Correlation analysis was performed using Spearman's correlation. The correlation between PDLIM2 and the immune score and stromal score was analyzed and plotted using "ggplot2, " "ggpubr, " and "ggextra. "

Co-expression analysis. We evaluated common immune checkpoint and immune marker genes. The coexpression relationship between PDLIM2 and these genes was calculated using limma package. A heat map of PDLIM2 co-expression with immune checkpoint genes was drawn using the R packages "reshape2" and "RColorBrewer. " All graphics and data analyses were completed on the R platform (3.6.3 version; The R Project for Statistical Computing, Vienna, Austria).

All methods were carried out in accordance with relevant guidelines and regulations.

The datasets obtained from public database.

Received: 13 July 2021; Accepted: 20 January 2022

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Cancer burden and trends in China: A review and comparison with Japan and South Korea

Cancer immunotherapy: Accomplishments to date and future promise

Cancer neoantigens and applications for immunotherapy

Immune-related adverse events induced by ICIs in advanced NSCLC: A meta-analysis and systematic review

Immune-related adverse events (irAEs): Diagnosis, management, and clinical pearls

Immuno-metabolism and microenvironment in cancer: Key players for immunotherapy

Tumor microenvironment and therapeutic response

Sequestration of PDLIM2 in the cytoplasm of monocytic/macrophage cells is associated with adhesion and increased nuclear activity of NF-kappaB

PDLIM2 a jeho role v onkogenezi-tumor supresor nebo onkoprotein? [PDLIM2 and its role in oncogenesis-tumor suppressor or oncoprote?

PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit

HSP70 mediates degradation of the p65 subunit of nuclear factor κB to inhibit inflammatory signaling

Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance

PDLIM2 regulates transcription factor activity in epithelial-to-mesenchymal transition via the COP9 signalosome

PDLIM2 restricts Th1 and Th17 differentiation and prevents autoimmune disease

PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer

PDLIM2 acts as a cancer suppressor gene in non-small cell lung cancer via the down regulation of NF-κB signaling

PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation

DNA methylation-dependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target

Tumor purity as an underlying key factor in glioma

Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer

PDZ and LIM domain-encoding genes: Molecular interactions and their role in development

Oncovirus Kaposi sarcoma herpesvirus (KSHV) represses tumor suppressor PDLIM2 to persistently activate nuclear factor κB (NF-κB) and STAT3 transcription factors for tumorigenesis and tumor maintenance

Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling

PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells

PDLIM2 suppression inhibit proliferation and metastasis in kidney cancer

PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D

ERK/MAPK signalling pathway and tumorigenesis

Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment

A review on the role of M2 macrophages in bladder cancer; pathophysiology and targeting

Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses

Foxp3 post-translational modifications and Treg suppressive activity

Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells

PD-1/PD-L1 pathway: Current researches in cancer

LAG3's enigmatic mechanism of action

Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer

Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma

Advances in cancer immunotherapy 2019-latest trends

Genomic approaches to understanding response and resistance to immunotherapy

Microsatellite instability: A predictive biomarker for cancer immunotherapy

PDLIM2: Signaling pathways and functions in cancer suppression and host immunity

Targeting the epigenetic regulation of antitumour immunity

Toward a shared vision for cancer genomic data

Visualizing and interpreting cancer genomics data via the Xena platform

The genotype-tissue expression (GTEx) project

GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis

Modeling Survival Data: Extending the Cox Model

limma powers differential expression analyses for RNA-sequencing and microarray studies

TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells

Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer

Inferring tumour purity and stromal and immune cell admixture from expression data

The results of this study are based on the data from TCGA database, UCSC Xena database,GTEx database,GEPIA2 database and TIMER database. We thank the authors who provided the data for this study. This study was supported by National Key Clinical Specialty Construction Project (Clinical Pharmacy) and High Level Clinical Key Specialty (Clinical Pharmacy) in Guangdong Province.

All authors contributed to study conception and design, Analysis of data and visualization of results were conducted by writing Y.Z. and D.L. Legends were modified by G.D. Supplementary Table were produced by M.G. The manuscript was written by Y.Z., D.L., M.G., G.D. and Y.C. were responsible for revising the manuscript. All authors read and approved the final manuscript. 

The authors declare no competing interests.

Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-05987-1.Correspondence and requests for materials should be addressed to Y.C.Reprints and permissions information is available at www.nature.com/reprints.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.